Skin Cancer/Melanoma

New Targets May Improve the Treatment of Rare Skin Cancer

June 16, 2021

While merkel cell carcinoma (MCC) tends to have poor prognoses and limited treatment options, promising response rates with checkpoint inhibitors may pave the way for better treatment for the rare skin cancer.

FDA Approves Cemiplimab for Advanced Basal Cell Carcinoma

February 09, 2021

The FDA approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.

Precision Medicine Highlights the Importance of Biomarkers in Melanoma

December 04, 2020

With the identification of actionable alterations, precision medicine continues to lead the way in all areas of oncology, but especially in melanoma, according to Jason J. Luke, MD, FACP, who added that, in order to successfully apply personalized therapy, it’s critical to be fluent in the differences between biomarkers.